# A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms

> **NCT03075826** · PHASE2 · COMPLETED · sponsor: **Weill Medical College of Cornell University** · enrollment: 22 (actual)

## Conditions studied

- Myeloproliferative Neoplasms

## Interventions

- **DRUG:** SGI-110

## Key facts

- **NCT ID:** NCT03075826
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-15
- **Primary completion:** 2021-03-31
- **Final completion:** 2021-03-31
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2022-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03075826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03075826, "A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03075826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*